Role of Cardiorespiratory Fitness in Modulating Cardiotoxicity in Long-Term Cancer Survivors Exposed to Anthracycline Therapy

BackgroundChildhood cancer survivors (CCS) often experience cardiotoxicity due to cancer treatment. Furthermore, low cardiorespiratory fitness (CRF) is a strong predictor of mortality. ObjectiveThis study investigates the effects of a 16-week supervised aerobic exercise intervention on CRF changes, as measured by VO2peak and parameters of cardiac structure and function via cardiac magnetic resonance imaging (CMR). MethodsCCS were enrolled >2 years post-treatment and underwent cardiotoxicity risk stratification, cardiopulmonary stress test to determine CRF, and CMR before and after exercise intervention. Subclinical myocardial dysfunction was assessed by segmental strain abnormality, with specific focus on the number of segments showing peak circumferential strain magnitude ({varepsilon}cc) [≤]10% and {varepsilon}cc [≤]17%. ResultsForty-seven subjects (10-25 years, median 22.0 years, IQR 9.0), 57.4% male, and 76% white were enrolled. Thirty-one patients completed the exercise intervention. VO2peak increased > 1 mL/kg/min in 16/31 (51.6%) of subjects. These subjects were labeled "responders", demonstrated a median increase in VO2peak of 3.8 mL/kg/min. Responders showed significant increase in left (p=0.0348) and right (p=0.0390) ventricular end diastolic volume and stroke volume index (p=0.0141). Left ventricular ejection fraction continued to decline in non-responders with a net difference of 2.45% favoring responders (p=0.007). At baseline, 11 subjects met high-risk definition based on segmental strain abnormalities (i.e. [≥]2 segments with peak circumferential strain magnitude ({varepsilon}cc) [≤]10% or [≥]9 segments [≤]17%). High risk subjects showed significant improvement in {varepsilon}cc with a post-intervention reduction in number of segments [≤]17% from 8.9 to 5.9 (p=0.014) and [≤]10% from 1.8 to 0.3 (p=0.022). ConclusionsCCS demonstrated increase in post-intervention VO2peak and improvement in CMR parameters of structure and function. Those classified as high-risk based on {varepsilon}cc abnormalities benefited the most. Trial registrationNCT, NCT04036032. Unique Protocol ID: 14-110. Registered 25 July 2019 - Retrospectively registered, https://classic.clinicaltrials.gov/ct2/show/NCT04036032